<DOC>
	<DOCNO>NCT01363284</DOCNO>
	<brief_summary>The purpose study identify , prior prescribe , neuropathic pain patient benefit duloxetine specific investigator aim : - Verify whether presence chronic pain alters pain modulation mechanism , DNIC ( diffuse noxious inhibitory control ) TS ( temporal summation ) . - Investigate whether anti-neuropathic medication duloxetine indeed change pain modulation profile , whether profile change associate reduction clinical pain .</brief_summary>
	<brief_title>Pretreatment Identification Duloxetine Success Neuropathic Pain Patients</brief_title>
	<detailed_description>There accept practice select among recommended medication individual neuropathic pain patient . Guidelines publish date provide evidence efficacy , however , data available choose right medication right patient order avoid long 'trial error 's . We hypothesize medication affect specific process pain modulation efficacious patient express dysfunction specific process . Therefore , medication enhance descend inhibition SSNRI efficacious patient less-efficient pain inhibition . The latter assess condition pain modulation ( CPM ) paradigm . Accordingly , aim study examine hypothesis painful diabetic neuropathy patient , use duloxetine , SSNRI agent assume augment descend pain inhibition reuptake inhibition noradrenalin serotonin spinal cord dorsal horn synapsis . We expect find good effect duloxetine patient whose pain inhibition capability less efficient , expressed baseline CPM . Further , aim evaluate whether pro-nocieptive pattern pain modulation indeed reverse response treatment . This explore compare CPM response treatment , correlate pain alleviation possible change CPM .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Patients diagnose painful diabetic neuropathy . Pain experience 3 month . Pain severity â‰¥ 4 010 scale ( last month average ) . Patient already receive duloxetine another SNRI/SSRI . Known hypersensitivity duloxetine inactive ingredient . Treatment monoamine oxidase inhibitor ( MAOI ) within 14 day randomization potential need use MAOI study within 5 day discontinuation study drug . Uncontrolled narrowangle glaucoma Because risk serious ventricular arrhythmia sudden death potentially associate elevate plasma level thioridazine ( Mellaril ) , Cymbalta thioridazine coadministered Inability perform psychophysical testing , due language perceptual barrier .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>